Bristol-Myers Squibb’s (BMY) oncology portfolio includes Opdivo, Empliciti, Sprycel, and Yervoy. The company reported a rise in sales for all these products during 2Q17 compared to 2Q16.
The above graph shows revenues for its oncology products over the last few quarters. Let’s look at these products in detail.
Opdivo, a human PD-1 blocking antibody, is approved for the treatment of various forms of cancer. For 2Q17, Opdivo reported revenues of $1.2 billion, a 42.0% rise from $840.0 million in 2Q16. The details about Opdivo and recent developments will be covered in the next part of this series.
Empliciti is a new oncology drug for the treatment of multiple myeloma, in combination with Celgene’s (CELG) Revlimid and dexamethasone in previously treated patients with multiple myeloma. Empliciti reported revenues of $55.0 million for 2Q17, a 62.0% rise from $34.0 million in 2Q16.
Sprycel is an oral inhibitor used for the treatment of Philadelphia chromosome positive chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Sprycel reported revenues of $506.0 million in 2Q17, a 12% rise from $451.0 million in 2Q16. The rise was driven by a strong performance for the drug in US markets.
Yervoy, a monoclonal antibody, is used for the treatment of certain types of melanoma. Yervoy reported revenues of $322.0 million in 2Q17, a 34.0% rise from $241.0 million in 2Q16. The rise was driven by a strong performance in US markets, partially offset by lower sales in international markets due to competition.
To divest the company-specific risks, investors can consider ETFs such as the Fidelity MSCI Healthcare ETF (FHLC), which holds 2.8% of its total assets in Bristol-Myers Squibb (BMY). FHLC also holds 10.3% in Johnson & Johnson (JNJ), 3.1% in Medtronic (MDT), and 2.4% in Abbott Laboratories (ABT).